KRAS is mutated in a wide array of human cancers, including PDA, colorectal, NSCLC, endometrial cancers, and cholangiocarcinoma, most of which are aggressive and resistant to conventional antineoplastic therapies [227, 228]. The gene discussed is KRAS; the disease is Patent ductus arteriosus.